Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
April 16, 2024 08:30 ET | Palisade Bio, Inc.
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces 1-for-15 Reverse Stock Split
April 03, 2024 17:30 ET | Palisade Bio, Inc.
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
March 27, 2024 08:00 ET | Palisade Bio, Inc.
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Provides Corporate Update and Reiterates Guidance
February 13, 2024 08:35 ET | Palisade Bio, Inc.
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe...
Palisade Bio_Logos(4.22)VSM.png
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
February 08, 2024 14:40 ET | Palisade Bio, Inc.
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
January 30, 2024 09:25 ET | Palisade Bio, Inc.
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
January 09, 2024 08:00 ET | Palisade Bio, Inc.
Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
IRBM_logos-no-strapline.png
IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders
July 12, 2023 03:00 ET | IRBM
Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’s ROME, July 12, 2023 (GLOBE NEWSWIRE) -- IRBM,...
IRBM_logos-no-strapline.png
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA
June 22, 2023 16:30 ET | IRBM
ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD...
IRBM_logos-no-strapline.png
IRBM Selected for Participation in National Chemical Biology Consortium
April 04, 2023 03:00 ET | IRBM
ROME, April 04, 2023 (GLOBE NEWSWIRE) -- IRBM, a drug discovery and early development research institute and global contract research organization, announces that it is joining the Chemical Biology...